Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition

View through CrossRef
<div>Abstract<p>Cancer stem cells (CSC) are capable of reconstructing cancer tissues, are involved in both recurrence and metastasis, and contribute to therapeutic resistance. Therefore, elucidating the molecular mechanism in CSCs is important to successfully treat unresectable cancers. Previously, we observed that colon cancer stem-like cells can be induced from human colon cancer cell lines by retrovirally introducing OCT3/4, SOX2, and KLF4, and we have designated such cells as induced cancer stem cells (iCSC). In the current study, we used iCSCs to evaluate the molecular mechanism of colon CSCs and developed new methods to control them. The spheres that were derived <i>in vitro</i> from the iCSCs, but not those from parental cells, mimicked human colon cancer tissues in terms of their immunohistologic patterns; therefore, sphere-forming ability was assessed as a measure of the tissue-reconstructing ability of iCSCs. Interestingly, the calcineurin inhibitor FK506 enhanced the sphere-forming ability of iCSCs, whereas GSK3 inhibition by RNAi, CHIR99021, and valproic acid (VPA) impeded the sphere-forming ability and expansion of iCSCs. FK506 and GSK3 inhibition showed the opposite effect regarding the NFATc3 localization of iCSCs. These data reveal the crucial role that NFAT localization, as regulated by calcineurin and GSK3, plays in the tissue-reconstructing ability of colon cancer stem cells and the potential of GSK3 inhibitors, such as VPA, in colon cancer stem cell–targeting therapy.</p><p><b>Implications:</b> This study identifies signaling pathways that contribute to the tissue-reconstructing capacity of colon CSCs and suggests that clinically used drugs could be repurposed to improve unresectable colon cancers. <i>Mol Cancer Res; 15(10); 1455–66. ©2017 AACR</i>.</p></div>
Title: Data from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition
Description:
<div>Abstract<p>Cancer stem cells (CSC) are capable of reconstructing cancer tissues, are involved in both recurrence and metastasis, and contribute to therapeutic resistance.
Therefore, elucidating the molecular mechanism in CSCs is important to successfully treat unresectable cancers.
Previously, we observed that colon cancer stem-like cells can be induced from human colon cancer cell lines by retrovirally introducing OCT3/4, SOX2, and KLF4, and we have designated such cells as induced cancer stem cells (iCSC).
In the current study, we used iCSCs to evaluate the molecular mechanism of colon CSCs and developed new methods to control them.
The spheres that were derived <i>in vitro</i> from the iCSCs, but not those from parental cells, mimicked human colon cancer tissues in terms of their immunohistologic patterns; therefore, sphere-forming ability was assessed as a measure of the tissue-reconstructing ability of iCSCs.
Interestingly, the calcineurin inhibitor FK506 enhanced the sphere-forming ability of iCSCs, whereas GSK3 inhibition by RNAi, CHIR99021, and valproic acid (VPA) impeded the sphere-forming ability and expansion of iCSCs.
FK506 and GSK3 inhibition showed the opposite effect regarding the NFATc3 localization of iCSCs.
These data reveal the crucial role that NFAT localization, as regulated by calcineurin and GSK3, plays in the tissue-reconstructing ability of colon cancer stem cells and the potential of GSK3 inhibitors, such as VPA, in colon cancer stem cell–targeting therapy.
</p><p><b>Implications:</b> This study identifies signaling pathways that contribute to the tissue-reconstructing capacity of colon CSCs and suggests that clinically used drugs could be repurposed to improve unresectable colon cancers.
<i>Mol Cancer Res; 15(10); 1455–66.
©2017 AACR</i>.
</p></div>.

Related Results

Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract Considering that a tumor promoting role for GSK3 has been suggested in pancreatic cancer (PC) cells and that GSK3 inhibitors are currently under clinical tr...
Data from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition
Data from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition
<div>Abstract<p>Cancer stem cells (CSC) are capable of reconstructing cancer tissues, are involved in both recurrence and metastasis, and contribute to therapeutic resi...
Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients
Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients
ObjectiveTacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypert...
GSK3 and Tau: Two Convergence Points in Alzheimer's Disease
GSK3 and Tau: Two Convergence Points in Alzheimer's Disease
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that plays a key role in the pathogenesis of Alzheimer's disease (AD). GSK3 phosphorylates tau...
The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes...
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
AbstractElraglusib (formerly 9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK3β) undergoing clinical trials for the treatment of various cancers includ...
SUMMARY
SUMMARY
SUMMARYThe purpose of the present monograph is to give an account of the distribution of fibrinolytic components in the organism, with special reference to the tissue activator of ...

Back to Top